This is a single-center, randomized, double-blind, placebo-controlled pilot study. A total of
40 patients who develop distributive shock, intra-operatively or post-operatively within 48
hours of heart transplant or left ventricular assist device placement will be enrolled.
Participants will be randomized to Angiotensin II (Giapreza) vs. placebo plus standard of
care, as a first line agent for vasoplegia. Two groups of patients will be enrolled:
- Group A: Heart Transplant (10 control, 10 treatment)
- Group B: LVAD implant (10 control, 10 treatment)